Spirair Nasal Septal Strap
Device Facts
| Record ID | K223167 |
|---|---|
| Device Name | Spirair Nasal Septal Strap |
| Applicant | Spirair, Inc. |
| Product Code | NHB · Ear, Nose, Throat |
| Decision Date | Aug 17, 2023 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 874.3620 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Spirair Nasal Septal Strap is used to support and straighten in septal cartilage when sufficient healthy cartilage exists, and the cartilage is appropriately mobilized utilizing standard septoplasty techniques.
Device Story
Bioabsorbable polydioxanone ribbon; 190 mm long; 0.65 mm thick; features barbed anchors for cartilage attachment. Used in nasal surgery by physicians; implanted during septoplasty to support/straighten septal cartilage. Device trimmed to size by surgeon; includes surgical needle attachment trimmed after use. Resorbed within 6 months. Provides mechanical support to septal cartilage; eliminates need for off-the-shelf sutures. Benefits patient by maintaining septal alignment during healing.
Clinical Evidence
Prospective, multi-center, multi-cohort early feasibility study (US site). Interim data (n=1) through 6 months showed device safe for implantation through resorption period. No adverse device effects reported; one procedure-related event consistent with traditional septoplasty.
Technological Characteristics
Bioabsorbable polydioxanone ribbon; 190mm x 0.65mm. Barbed anchor design for tissue fixation. Sterile, single-use. Biocompatibility per ISO 10993-1. Permanent implant (>30 day) classification.
Indications for Use
Indicated for patients requiring support and straightening of minor septal cartilage deviations, provided sufficient healthy cartilage exists and is mobilized via standard septoplasty.
Regulatory Classification
Identification
Ear, nose, and throat synthetic polymer material is a device material that is intended to be implanted for use as a space-occupying substance in the reconstructive surgery of the head and neck. The device is used, for example, in augmentation rhinoplasty and in tissue defect closures in the esophagus. The device is shaped and formed by the suregon to conform to the patient's needs. This generic type of device is made of material such as polyamide mesh or foil and porous polyethylene.
Predicate Devices
- Spirox INEX Implantable Sheet (K132920)
Reference Devices
- StratafixTM Symmetric PDSTM Plus, Knotless Tissue Control (K141776)
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains two logos. On the left is the Department of Health & Human Services logo. On the right is the FDA logo, which includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
August 17, 2023
Spirair, Inc. Tracey Henry Regulatory Consultant 6084 Monterev Hwv. 108 San Jose, California 95138
Re: K223167
Trade/Device Name: Spirair Nasal Septal Strap Regulation Number: 21 CFR 874.3620 Regulation Name: Ear, Nose, And Throat Synthetic Polymer Material Regulatory Class: Class II Product Code: NHB Dated: July 17, 2023 Received: July 17, 2023
Dear Tracey Henry:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
{1}------------------------------------------------
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Joyce C. Lin -S
for Shu-Chen Peng, Ph.D. Assistant Director DHT1B: Division of Dental and ENT Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known) K223167
Device Name Spirair Nasal Septal Strap
Indications for Use (Describe)
The Spirair Nasal Septal Strap is used to support and straighten in septal cartilage when sufficient healthy cartilage exists, and the cartilage is appropriately mobilized utilizing standard septoplasty techniques.
| Type of Use (Select one or both, as applicable) | <table><tr><td><span> Residential Use (Single-DETACHED Dwelling) </span></td><td><span> Transient Occupancy Use (Hotel, Dormitory, etc.) </span></td></tr></table> | <span> Residential Use (Single-DETACHED Dwelling) </span> | <span> Transient Occupancy Use (Hotel, Dormitory, etc.) </span> |
|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------------|
| <span> Residential Use (Single-DETACHED Dwelling) </span> | <span> Transient Occupancy Use (Hotel, Dormitory, etc.) </span> | | |
X Prescription Use (Part 21 CFR 801 Subpart D)
| | Over-The-Counter Use (21 CFR 801 Subpart C)
## CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
## 510(k) Summary
#### I. SUBMITTER
Spirair, Inc. 6084 Monterey Hwy, #108 San Jose, CA 95138 Phone: (844) 434-9673
Contact Person: James Kintzing, CEO Date Prepared: August 15, 2023
#### II. DEVICE
| Name of Device: | Spirair Nasal Septal Strap |
|-----------------------|------------------------------------------------------|
| Common or Usual Name: | Ear, Nose, Throat Synthetic Polymer Material |
| Classification Name: | Polymer, Ear, Nose and Throat, Synthetic, Absorbable |
| Regulatory Class: | Class II |
| Product Code: | NHB |
| Regulation Number: | 21 CFR 874.3620 |
#### III. PREDICATE/REFERENCE DEVICE
| Predicate Device: | Spirox INEX Implantable Sheet (K132920) |
|-------------------|------------------------------------------------------------------------|
| Reference Device: | StratafixTM Symmetric PDSTM Plus, Knotless Tissue Control<br>(K141776) |
#### IV. DEVICE DESCRIPTION
The Spirair Nasal Septal Strap is a bioabsorbable, polydioxanone ribbon that is intended to be used in nasal surgery. The Nasal Septal Strap is 190 mm long and 0.65 mm thick with barbed features ("anchors") which enable attachment to and support of nasal septal cartilage. The Nasal Septal Strap is trimmed to size by the physician to suit the anatomical conditions and clinical use case. The device includes a surgical needle attachment to the tissue which is trimmed off after use. The Nasal Septal Strap is provided sterile as a single use device and when permanently implanted, is resorbed within a 6-month period.
#### V. INDICATIONS FOR USE
The Spirair Nasal Septal Strap is used to support and straighten minor deviations in septal cartilage when sufficient healthy cartilage exists, and the cartilage is appropriately mobilized utilizing standard septoplasty techniques.
{4}------------------------------------------------
### VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
The Nasal Septal Strap (subject device) has the same intended use and fundamental technology as the predicate device, Spirox INEX Implantable Sheet.
The subject device shares similar technological characteristics with the predicate device (i.e., principle of operation, mechanical properties, bioabsorbable material, biocompatibility, sterility). Like the predicate device, the subject device can be trimmed to size and implanted using standard surgical tools and techniques.
The subject device also includes features that enable surgical implantation without the use of off-the-shelf sutures required for the predicate. These features are equivalent to the surgical tools used to implant the predicate device and therefore do not introduce any different questions of safety or effectiveness. These features are also similar to the design of the reference device, Stratafix™ Symmetric PDSTM Plus, Knotless Tissue Control, and were tested using similar testing methodologies as the reference device in support of substantial equivalence.
#### VII. PERFORMANCE DATA
The following performance data were provided in support of the substantial equivalence determination.
| Performance<br>Testing | Data provided |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Biocompatibility<br>Testing | The biocompatibility evaluation for the Nasal Septal Strap was conducted in accordance with ISO 10993-1, Biological Evaluation of medical devices – Part 1: Evaluation and testing within a risk management process (2018) and FDA Guidance: Use of International Standard ISO 10993-1, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process, September 4, 2020. This evaluation determined that the materials in the Nasal Septal Strap do not pose a risk of negative interaction with patients.<br><br>The implantable portion of the Nasal Septal Strap was assessed as a Permanent Implant (>30 Day) whereas the surgical needle was tissue contacting with Limited (<24 hour) duration. The following tests were performed:<br>• Cytotoxicity<br>• Sensitization<br>• Irritation<br>• Implantation<br>• Chemical characterization |
| Distribution,<br>Packaging and<br>Shelf-Life<br>Testing | Distribution testing and Accelerated Aging of the Nasal Septal Strap was successfully completed.<br><br>Final packaging and device performance were successfully tested demonstrating integrity of the sterile barrier and preservation of the Nasal Septal Strap properties for the labeled shelf-life. |
{5}------------------------------------------------
| Performance<br>Testing | Data provided |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Performance<br>Testing – Bench | Design verification testing was performed on the Nasal Septal Strap and demonstrated that the physical and functional requirements were met.<br>Specifically, the following was tested:<br>● Mechanical properties<br>● Material properties<br>● Migration of implant<br>● <i>In vitro</i> degradation |
| Performance<br>Testing –<br>Animal | <i>In vivo</i> implantation was performed in an GLP animal study and demonstrated device safety, degradation, and biocompatibility performance of the device. |
| Performance<br>Testing –<br>Clinical | Safety data from a clinical study was included to support the <i>in vivo</i> implantation of the Nasal Septal Strap in septal nasal cartilage. These data were collected as part of a prospective, multi-center, multi-cohort, early feasibility study from one US site. Limited interim data was available out to six months and demonstrated that the Nasal Septal Strap was safe for implantation in nasal septal cartilage through the resorption period.<br><br>There were no adverse device effects reported. There was (1) procedure-related event reported in one (1) subject; adverse event was not unanticipated and reported in traditional septoplasty procedures. |
#### VIII. CONCLUSIONS
In conclusion, the intended use is the same as that of the predicate device. Performance testing shows that any differences in indications for use, and technological characteristics from the predicate device do not affect safety and effectiveness, and demonstrates that the subject device is substantially equivalent to the predicate device.
